<DOC>
	<DOCNO>NCT00250874</DOCNO>
	<brief_summary>To study pharmacokinetic profile therapeutic schedule order demonstrate absence negative interaction among 3 drug administer</brief_summary>
	<brief_title>Myocet , Docetaxel &amp; Trastuzumab 1st Line Treatment Patients With HER-2/Neu Positive Metastatic Breast Cancer</brief_title>
	<detailed_description>1 . To assess maximum tolerate dose ( MTD ) Myocet different dosage combination Taxotere fix dose 35 mg/m2 day 2 9 every 21 day weekly Herceptin first line therapy patient affect HER-2/neu positive metastatic breast cancer 2 . To enhance proportion complete remission 3 . To allow feasibility combination Herceptin Myocet Taxotere without enhance risk cardiotoxicity</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>HER2/neu overexpression assess FISH test immunohistochemical method : Dako ( result must 3+ dakotest ) ; immunohistochemical test result 2+ need positive FISH test Female &lt; 70yrs Histologically cytologically proven breast cancer . Metastatic locally advance breast cancer ( clinical stage : IIIIV ) Adequate hematological , hepatic , renal cardiac function , latter confirm echocardiography FEVS ≥50 % Prior adjuvant chemotherapy doxorubicin total dose ≤300 mg/m2 , epirubicin total dose ≤450 mg/m2 History cardiopathy Severe hepatic renal disease Brain metastasis parameter disease Contraindication use corticosteroid premedication Acute infectious disease Insulindependent diabetes History cancer except adequately treat basal cell skin cancer situ carcinoma cervix Concurrent treatment cancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>